Literature DB >> 6090179

Possible involvement of opiate receptors in the pharmacological profiles of antidepressant compounds.

K E Isenberg, T J Cicero.   

Abstract

Tricyclic antidepressants and selected hydroxylated metabolites were found to inhibit [3H]naltrexone binding in whole rat brain. The drug concentrations required to inhibit binding appeared to be within pharmacological relevant brain concentrations. Carbamazepine and several monoamine oxidase inhibitors (with the exception of clorgyline) were inactive in this regard. The relative potency of the tricyclic antidepressants with regard to inhibitions of opiate binding in brain did not correlate with their clinical efficiency as antidepressants, suggesting that these compounds probably do not exert their antidepressant effects through opioid peptidergic systems in brain. In addition, we found that imipramine (30 mg/kg) had antinociceptive properties, as assessed by the hot plate procedure, which were partially, but not significantly, reversed by naloxone (2 mg/kg). The possibility that opioid receptors may be involved in the analgesic properties of the tricyclic antidepressants has been discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6090179     DOI: 10.1016/0014-2999(84)90189-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  Antidepressants as analgesics: an overview of central and peripheral mechanisms of action.

Authors:  J Sawynok; M J Esser; A R Reid
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

2.  WAY-318068: a novel, potent and selective noradrenaline re-uptake inhibitor with activity in rodent models of pain and depression.

Authors:  G T Whiteside; J M Dwyer; J E Harrison; C E Beyer; T Cummons; L Manzino; L Mark; G H Johnston; B W Strassle; A Adedoyin; P Lu; M J Piesla; C M Pulicicchio; J C L Erve; B J Platt; Z A Hughes; K E Rogers; D C Deecher; E J Trybulski; J D Kennedy; P Zhang; L Leventhal
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

3.  Noradrenergic and opioid mediation of tricyclic-induced reversal of escape deficits caused by inescapable shock pretreatment in rats.

Authors:  P Martin; P Soubrié; P Simon
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors.

Authors:  Maria C Olianas; Simona Dedoni; Pierluigi Onali
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

5.  Evidence for a differential opioidergic involvement in the analgesic effect of antidepressants: prediction for efficacy in animal models of neuropathic pain?

Authors:  A-S Wattiez; F Libert; A-M Privat; S Loiodice; J Fialip; A Eschalier; C Courteix
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 6.  How do drugs relieve neurogenic pain?

Authors:  R Karlsten; T Gordh
Journal:  Drugs Aging       Date:  1997-11       Impact factor: 3.923

7.  Imipramine decreases oesophageal pain perception in human male volunteers.

Authors:  P L Peghini; P O Katz; D O Castell
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

8.  Study of the clomipramine-morphine interaction in the forced swimming test in mice.

Authors:  A Eschalier; J Fialip; O Varoquaux; M C Makambila
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

9.  Milnacipran inhibits glutamatergic N-methyl-D-aspartate receptor activity in spinal dorsal horn neurons.

Authors:  Tatsuro Kohno; Masafumi Kimura; Mika Sasaki; Hideaki Obata; Fumimasa Amaya; Shigeru Saito
Journal:  Mol Pain       Date:  2012-06-19       Impact factor: 3.395

10.  Effect of the combined use of tramadol and milnacipran on pain threshold in an animal model of fibromyalgia.

Authors:  Seong-Ho Kim; Junhwa Song; Hyunil Mun; Keon Uk Park
Journal:  Korean J Intern Med       Date:  2009-06-08       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.